Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:
- Unique arrangement structures at specific product life cycle stages
- Protecting IP
- Avoiding short-term fallout
- The impact of collaboration on future growth and exit strategies
- Strategies from both sides of the agreement: increasing the opportunity for future collaborations
Panelists:
- Richard A. Kaufman, Partner, Foley & Lardner LLP
- Richard Bork, Corporate Patent Counsel, Novo Nordisk
- Tim Opler, Ph.D., Principal, Torreya Partners
- Thomas Beetham, Senior Corporate Counsel, Genzyme
- Michael Lytton, Executive Vice President, Corporate and Business Development, Biogen Idec
Related Insights
10 February 2025
Foley Viewpoints
New Consumer Financial Protection Bureau Acting Director Expands Freeze to All CFPB Activities; CFPB Office Closes
On Friday, February 7, 2025, President Trump named newly confirmed director of the Office of Management and Budget, Russell Vought, as acting director of the CFPB.
10 February 2025
Labor & Employment Law Perspectives
It’s That Time of Year Again: Using OSHA’s Injury Tracking Application to Submit OSHA Forms 300, 300A, and 301
Pursuant to the Occupational Safety and Health Administration’s (OSHA) electronic reporting regulation, covered employers must submit their OSHA injury and illness records (OSHA Forms 300, 300A, and 301) using OSHA’s electronic Injury Tracking Application by March 2, 2025.
10 February 2025
Labor & Employment Law Perspectives
Trump Administration Provides Some Guidance on DEI Programs
Following up on the Trump Administration’s series of executive orders and statements regarding diversity, equity, inclusion, and accessibility (DEI or DEIA) programs, on February 5, 2025, both the Office of Personnel Management (OPM) and the United States Attorney General Office issued memoranda reflecting additional guidance as to what may constitute an “illegal” DEI or DEIA program and directing enforcement action.